Interactions between extracellular matrix (ECM) and mammary epithelial cells are critical for mammary gland homeostasis and apoptotic signaling. Interferon regulatory factor-1 (IRF-1) is a transcriptional regulator that promotes apoptosis during mammary gland involution and p53-independent apoptosis. We have recently shown that rapid cell surface tamoxifen (Tam) signaling promotes apoptosis in normal human mammary epithelial cells that were acutely damaged by expression of human papillomavirus type-16 E6 protein (*HMEC-E6). Apoptosis was mediated by recruitment of CREB-binding protein (CBP) to the c-activating sequence (GAS) element of the IRF-1 promoter, induction of IRF-1 and caspase-1/-3 activation. Here, we show that growth factor-depleted, reconstituted ECM (rECM), similar to Tam, promotes apoptosis in *HMEC-E6 cells through induction of IRF-1. Apoptosis was temporally associated with recruitment of CBP to the GAS element of the IRF-1 promoter, induction of IRF-1 expression and caspase-1/-3 activation. Small interfering RNA-mediated suppression of IRF-1 protein expression in *HMEC-E6 cells blocked (1) induction of IRF-1, (2) caspase-1/-3 activation and (3) apoptosis. These observations demonstrate that IRF-1 promotes rECM-mediated apoptosis and provide evidence that both rECM and rapid Tam signaling transcriptionally activate IRF-1 through recruitment of CBP to the IRF-1 GAS promoter complex.
Introduction
Interferon regulatory factor-1 (IRF-1) was originally identified as a DNA-binding factor on the mouse interferon beta (IFN-b) promoter and is known to play an important role in promoting apoptosis in response to viral infections (Miyamoto et al., 1988) . IRF-1 can be induced by type II-IFN (IFN-g) (Romeo et al., 2002) and is known to participate in both p53-dependent and -independent apoptotic signaling (Tamura et al., 1995; Tanaka et al., 1996) . Recently, IRF-1 was shown to participate in both type IFN-g and anti-estrogen ICI 182 780 p53-independent apoptotic signaling in human breast cancer cell lines (Bouker et al., 2004; Porta et al., 2005) . Taken together, these observations suggest that IRF-1 plays a role in p53-independent apoptotic signaling in mammary epithelial cells.
There is also growing evidence that IRF-1 plays an important role in mammary gland homeostasis and hormone responsiveness. IRF-1 has been implicated to be involved in ICI 182 780 anti-estrogen resistance in breast cancer (Gu et al., 2002) . IRF-1 is induced by the estrogen agonist/antagonist, tamoxifen (Tam) and the pure estrogen antagonist, ICI 182 780 (Bouker et al., 2004; Bowie et al., 2004) . Taken together, these observations support the role of IRF-1 signaling in mammary gland homeostasis and estrogen/anti-estrogen signaling.
The 'classic' or genomic mechanism of 17-b-estradiol (E2) action requires the presence of the estrogen receptor (ER), the E2/ER complex binding to an estrogen response element and changes in both transcription and translation. However, recent evidence suggests that estrogen, and anti-estrogens, may also act through rapid, 'non-classic' signaling pathways in human mammary epithelial cells (HMECs) (Kelly and Levin, 2001; Marquez and Pietras, 2001; Dietze et al., 2004) . Unlike ER( þ ) human breast cancers, HMECs typically express low nuclear levels of ER (ER-'poor'). Although HMECs are ER-'poor', unlike ER(À) breast cancer cells, HMECs are not Tam-resistant. We recently demonstrated that although therapeutic levels of Tam (1.0 mM) promoted growth arrest in HMEC controls, equimolar concentrations of Tam induced apoptosis in ER-'poor' *HMEC-E6 through a rapid, 'non-classic' signaling pathway Bowie et al., 2004) . Tam induced apoptosis in *HMEC-E6 cells through (1) rapid cell-surface-mediated modulation of AKT phosphorylation, (2) recruitment of STAT1 and the coactivator, CREB-binding protein (CBP), to the g-activating sequence (GAS) element of the IRF-1 promoter and (3) induction of IRF-1 Dietze et al., 2004) . These observations suggest a role for IRF-1 in regulating rapid Tam signaling and promoting p53-independent apoptosis in *HMEC-E6 cells.
Carcinogenesis is thought to be a multistep process resulting from the accumulation of genetic damage. However, not all damaged mammary epithelial cells progress to become invasive breast cancers and, instead, are thought to be eliminated by apoptosis. Breast tissue is composed of mammary epithelial cells that rest on extracellular matrix (ECM). Interactions between epithelial cells and ECM regulate mammary gland homeostasis by promoting a coordinated balance between proliferation and apoptosis (Folkman and Moscona, 1978; Petersen et al., 1992; Farrelly et al., 1999; Stupack and Cheresh, 2002) .
Laminins are heterotrimeric ECM glycoproteins that mediate many of the regulatory functions of ECM (Aberdam et al., 2000) . Laminin-5 (a3A, b3 and g2) is the most abundant ECM glycoprotein produced by mammary epithelial cells (D'Ardenne et al., 1991) . Our prior studies showed that although contact with reconstituted ECM (rECM) promoted growth arrest in HMEC controls, contact between rECM and *HMEC-E6 cells promotes p53-independent apoptosis through a laminin-5/a3b1-integrin signaling pathway; interruption of laminin-5/a3b1-integrin signaling blocked apoptosis Dietze et al, 2005) . Given the observations that IRF-1 is important for response to acute cellular damage and p53-independent apoptotic signaling in mammary epithelial cells and our recent observation that Tam promotes p53-independent apoptosis in *HMEC-E6 cells through induction of IRF-1 Dietze et al., 2004) , we hypothesized that rECM may also promote p53-independent apoptosis in *HMEC-E6 cells through induction of IRF-1. Here, we show that rECM, similar to Tam, promotes recruitment of STAT1 and CBP to the GAS element of the IRF-1 promoter and subsequent induction of IRF-1. These results provide evidence that Tam and rECM signal through IRF-1 and support a more global role of IRF-1 in mediating p53-independent apoptosis in mammary epithelial cells.
Results rECM activates caspases-1/-3 and induces apoptosis in *HMEC-E6 cells Here, we tested in large-scale three-dimensional, highdensity liquid rECM culture (3-hD) whether rECM, similar to Tam, activates caspases-1 and -3 and promotes apoptosis in *HMEC-E6 cells. HMECs are plated at high density (2.5 Â 10 7 /25 cm 2 ) on a nonadhesive substrate as described in Materials and methods, and treated with a 1:100 dilution of growth factor-depleted rECM in Standard Media. *HMEC-E6 cells and passage matched HMEC-LX controls detach from the non-adhesive substrate starting at 6 h and spontaneously form 20-30 micron cellular aggregates in a liquid solution of growth factor-depleted rECM diluted in tissue culture media (Figure 1a and f). HMEC-LX and *HMEC-E6 cells undergo growth arrest at 6-7 h whereas only *HMEC-E6 cells undergo apoptosis at 12-24 h (Figure 1b and c) .
We previously observed that 1.0 mM Tam promotes growth arrest and apoptosis in *HMEC-E6 cells but growth arrest alone in HMEC-LX cells . Apoptosis in Tam-treated *HMEC-E6 cells was first observed at 12 h. Similarly, *HMEC-E6 cells grown in 3-hD culture demonstrated Annexin-V binding first at 12 h (Figure 1c) . In contrast, rECM-treated, HMEC-LX controls did not undergo apoptosis (Figure 1c) .
We previously demonstrated that Tam-induced apoptosis in *HMEC-E6 cells was dependent on sequential activation of caspases-1/-3 . We also demonstrated that rECM (1) promotes apoptosis in *HMEC-E6 cells through laminin-5/a3b1-integrin signaling and (2) interruption of laminin-5/a3b1-integrin signaling blocks apoptosis Dietze et al., 2005) . Here, we tested whether rECM-induced apoptosis was similarly associated with caspase-1/-3 activation, and whether a3-/b1-integrin blocking antibodies could inhibit caspase activation. *HMEC-E6 cells grown in 3-hD culture demonstrated caspase-1 and -3 activation first at 3 and 12 h, respectively. Pretreatment of *HMEC-E6 cells with a3-/b1-integrin blocking antibodies inhibited the activation of caspase-1 and -3 ( Figure 1d , e and f). These data show that (1) rECM, similar to Tam, promotes apoptosis in *HMEC-E6 cells associated with activation of caspases-1/-3 and (2) pretreatment of *HMEC-E6 with a3-/b1-integrin blocking antibodies inhibited caspase activation.
rECM-induced gene transcripts
To investigate the molecular mechanism of rECMinduced apoptosis in *HMEC-E6 cells, we analysed the expression profiles of early passage *HMEC-E6 cells and HMEC-LX controls in 3-hD rECM culture. We previously reported that treatment with 1.0 mM Tam induced IFN-stimulated genes (ISGs) in *HMEC-E6 cells . Surprisingly, rECM treatment induced a similar subset of ISGs (Table 1) . Sixteen rECM-induced ISGs were also induced in *HMEC-E6 cells by Tam, including IRF-1. This latter finding is important because we have previously shown that IRF-1 regulates Tam-induced, p53-independent apoptosis in *HMEC-E6 cells .
Differential gene expression was confirmed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) in triplicate, and normalized to beta-actin, for five ISGs (Figure 2a) . Importantly, even though some ISGs are slightly induced by rECM in HMEC-LX controls, IRF-1 was not induced . Based on these similar patterns of ISG induction, we hypothesized that both Tam-and rECMmediated apoptosis in *HMEC-E6 cells may activate a similar downstream pathway that utilizes IRF-1 and possibly other ISGs.
rECM does not induce IFN-a, -b or -g Enzyme-linked immunosorbent assays (ELISA) tested for IFN-a, -b and -g production at 0, 30 min, 1, 2 and 4 h. IFN production was not detected (data not shown). These observations are consistent with our previous observation that Tam promotes induction of IRF-1/ ISGs and apoptosis in *HMEC-E6 cells in the absence of IFN production or secretion . These experiments demonstrated that rECM and 1.0 mM Tam initiate apoptosis through different upstream targets.
rECM promotes recruitment of CBP and STAT1 to the IRF-1 GAS element Type II-IFN (IFN-g) signaling has been shown to promote p53-independent apoptosis (Ossina et al., 1997; Porta et al., 2005) . We previously demonstrated that treatment of *HMEC-E6 cells with 1.0 mM Tam promotes formation of a STAT1 complex on the IRF-1 GAS element, recruitment of cofactor CBP and upregulation of IRF-1 messenger RNA (mRNA). Here, we investigated whether induction of IRF-1 by rECM in *HMEC-E6 cells grown in 3-hD culture was due to the formation of a similar transcriptional complex on the IRF-1 GAS element. Western analysis was conducted to test for STAT1 expression and its phosphorylation. As we reported previously for Tam-induced apoptosis , STAT1 was active at baseline in untreated *HMEC-E6 cells (Figure 3a) . Treatment of *HMEC-E6 cells with rECM increased STAT1 phosphorylation at Ser727 by 2.5-fold (Po0.005) at 1 h, whereas total STAT1 levels remained unchanged (Figure 3a and b) . 
Abbreviations: ECM, extracellular matrix; Tam, tamoxifen. Fold change >1.5; P-value o0.05. IRF-1 regulates ECM-mediated apoptosis ML Bowie et al Chromatin immunoprecipitation (ChIP) studies were performed to test whether rECM, similar to Tam, promotes the formation of a STAT1/CBP complex on the IRF-1 GAS element. HMEC-LX control and *HMEC-E6 cells were grown in 3-hD rECM culture. As shown in Figure 3d , STAT1 was bound to the IRF-1 GAS element in the *HMEC-E6 cells at baseline and during rECM treatment whereas CBP was recruited to the GAS element only after rECM treatment. Neither STAT1 nor CBP was recruited to the IRF-1 GAS element in HMEC-LX control cells (Figure 3c ). These observations indicate that STAT1 and CBP binding to the IRF-1 GAS element may play a role in IRF-1 induction during rECM-mediated apoptosis in *HMEC-E6 cells.
To further test the association of STAT1 with the IRF-1 GAS element, immunoprecipitation using a biotin-labeled oligonucleotide containing the IRF-1 GAS promoter element was performed in *HMEC-E6 cells grown in 3-hD culture. Consistent with the ChIP results, STAT1 was associated with the GAS element at baseline (Figure 3d and e). As seen in Figure 3e , rECM promoted increased STAT1 association with the IRF-1 promoter GAS element by 1 h.
IRF-1 induction
To further investigate the role of rECM in promoting apoptosis in *HMEC-E6 cells, we tested for mRNA and protein levels as a function of rECM treatment. Semiquantitative RT-PCR showed that rECM promoted significant induction of IRF-1 mRNA in *HMEC-E6 cells at 1 h (9.1-fold) but not in HMEC-LX cells (Figure 4a and b) . Consistent with mRNA expression results, rECM promoted a 2.5-fold increase in IRF-1 protein expression in *HMEC-E6 cells at 1 h (Figure 4c and d) . 
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caspase-1 and -3 and apoptosis . Here, we similarly investigated whether suppression of IRF-1 in *HMEC-E6 cells blocked rECM-mediated caspase-1 and -3 activation and apoptosis in 3-hD culture. IRF-1 was suppressed using our previously published small interfering RNA (siRNA) oligo sequences directed against IRF-1 ( Bowie et al., 2004) . Consistent with our prior results, treatment with IRF-1 #1 and IRF-1 #4 siRNA oligos for 12 h suppressed baseline IRF-1 (1) mRNA expression by 60 and 75%, respectively ( Figure 5a ) and (2) protein expression by 95 and 97%, respectively (Figure 5b ). IRF-1 siRNAs #1 and #4 also blocked rECM-mediated induction of IRF-1 mRNA in *HMEC-E6 cells (Figure 5c ).
Suppression of IRF-1 with siRNA oligos in *HMEC-E6 cells blocked rECM-mediated apoptosis as evidenced by a lack of caspase-1/-3 activation in 3-hD rECM culture. *HMEC-E6 cells pretreated with IRF-1 #1 or IRF-1 #4 siRNA oligos for 12 h and grown in 3-hD rECM did not show activation of caspase-1 or -3 (Figure 5d and e) . In addition, we tested whether stable suppression of IRF-1 would inhibit rECM-induced activation of caspase-3 in *HMEC-E6 cells at 48 h. *HMEC-E6 cells were transfected with the pSilencer4.1-CMV puro vector containing either the IRF-1 #1 siRNA target sequence or the control siRNA nonspecific sequence, and IRF-1 suppression was confirmed by Western analysis (Figure 6a ). *HMEC-E6 cells with stable suppression of IRF-1 failed to activate caspase-3 upon 48 h of rECM culturing (Figure 6b ).
We next tested if overexpression of IRF-1 in HMEC-LX controls sensitized them to rECM-mediated apoptosis. An exogenous IRF-1 construct was expressed in HMEC-LX cells using an IRES2 DsRed2 vector; control cells expressed the IRES2 DsRed2 empty vector alone (Figure 6c Before rECM exposure, cells were pretreated for 12 h with oligos, either IRF-1-specific siRNA #1 (si#1), IRF-1-specific siRNA #4 (si#4), or nonspecific control siRNA (cont siRNA). (d, e) rECMmediated caspase-1 and -3 activation in *HMEC-E6 cells is blocked by suppression of IRF-1. Before growth in 3-hD rECM culture, cells are pretreated for 12 h with either IRF-1-specific siRNA oligos #1 (siRNA #1), IRF-1-specific siRNA #4 (siRNA #4), (cellfectin) cellfectin treatment alone, or nonspecific control siRNA (control siRNA). Cells that do not receive siRNA or cellfectin are designated as control (control). *Significantly different from controls, Po0.002.
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ML Bowie et al rECM induces IFI 6-16 mRNA IRF-1 expression induces transcription of IFI 6-16, and it has been previously shown that IRF-1 directly binds to the IFN-stimulated response element (ISRE) within the IFI 6-16 promoter (Parrington et al., 1993; Henderson et al., 1997 Figure 2a ). As both Tam and rECM signals converge on the induction of IRF-1, we further investigated whether a downstream target of IRF-1, IFI 6-16, was similarly upregulated by rECM culturing in *HMEC-E6 cells. IFI 6-16 mRNA was induced in *HMEC-E6 cells at 1 h, whereas HMEC-LX control cells showed no induction of IFI 6-16 (Figure 7a and b) .
ISGF3 and IRF-1 binding to the ISRE in the IFI 6-16 promoter temporally correlates with transcriptional activation of IFI 6-16 IFI 6-16 has been shown to be strongly induced by Type I-IFN (IFN-a/b) signaling and weakly induced by Type II-IFN (IFN-g) signaling (Kelly et al., 1986) . Induction of IFI 6-16 expression by Type I IFNs has been shown to be mediated by binding of the ISGF3 complex (STAT1/STAT2/IRF-9) to the ISRE element of the IFI 6-16 promoter (Kelly et al, 1986) . It has been shown that upon IFN-a treatment, ISGF3 binds rapidly to the IFI 6-16 ISRE, followed by the recruitment of IRF-1 at 1-2 h Levy et al., 1988) . Furthermore, the binding of IRF-1 upon IFN-a treatment corresponds to maximal and sustained IFI 6-16 transcription. Without IRF-1 binding the level of IFI 6-16 transcription falls off, suggesting that IRF-1 is required to stabilize the ISGF3 complex (Imam et al., 1990) . However, following treatment with IFN-g, recruitment of IRF-1 alone to the IFI 6-16 ISRE site also has been shown to promote IFI 6-16 expression (Henderson et al., 1997) . We tested whether transcriptional activation of IFI 6-16 temporally correlated with recruitment of either the ISGF3 complex (STAT1/STAT2/IRF-9) or IRF-1/CBP to the IFI 6-16 ISRE. Exposure of *HMEC-E6 to rECM for 30 min was associated with a 3.1-fold and 2.2-fold respective increase in IRF-9 and STAT2 protein expression (Figure 7c ). ChIP analysis demonstrated that in rECM-treated *HMEC-E6 cells, IRF-9 and STAT1 were recruited to the IFI 6-16 ISRE promoter element by 30 min (Figures 7d and e) . IRF-9 is the final DNAbinding factor recruited to the ISGF3 complex and is required for transcriptional activation (Veals et al., 1992) . Therefore, these observations show that treatment of *HMEC-E6 cells with rECM for 30 min promotes recruitment of the ISGF3 complex to the IFI 6-16 ISRE promoter element and precedes transcriptional activation of IFI 6-16 at 60 min.
We next tested the same lysates from *HMEC-E6 cells for the recruitment of IRF-1 and CBP to the IFI 6-16 ISRE element. Both IRF-1 and CBP were recruited to the IFI 6-16 ISRE promoter element in *HMEC-E6 cells at 60 min (Figure 7f ). Recruitment was temporally associated with IFI 6-16 mRNA induction at 60 min (Figure 7a-f) . Taken together, these data show that the ISGF3 complex is recruited to the IFI 6-16 ISRE promoter element at 30 min, followed by IRF-1 and CBP recruitment by 60 min. The presence of this transcriptional complex correlates with the transcriptional activation of IFI 6-16 at 60 min. As Tam also promotes recruitment of STAT1/CBP/IRF-1 to the IFI 6-16 ISRE during the induction of IFI 6-16, this provides evidence that Tam and rECM signal through IRF-1/CBP and target a common set of downstream genes.
Discussion
Here, we demonstrate that rECM promotes apoptosis in *HMEC-E6 cells through recruitment of CBP to the IRF-1 GAS element and induction of IRF-1. CBP is known to be a transcriptional regulator of both IFN and steroid/thyroid signaling (Robyr et al., 2000) and an important mediator of proliferation and apoptosis (Goodman and Smolik, 2000; Vo and Goodman, 2001) . We previously demonstrated that suppression of CBP results in loss of rECM growth regulation, polarity and apoptosis . Recently, we showed that CBP regulates mammary epithelial cell proliferation and apoptosis through recruitment of CBP to the LAMA3A promoter and transcriptional activation of laminin-5 (Dietze et al., 2005) . These observations suggest that loss of CBP signaling may promote early mammary carcinogenesis through loss of sensitivity to rECM-mediated growth regulation and apoptosis.
We observe here that contact between *HMEC-E6 cells and rECM promotes recruitment of CBP to the IRF-1 GAS element, IRF-1 induction and apoptosis, whereas suppression of IRF-1 blocks apoptosis. CBP has been previously shown to be a transcriptional regulator of ISGs, including IRF-1. Similar to our observation here with rECM, we recently observed that Tam promotes apoptosis in *HMEC-E6 cells, in the absence of IFN production, through recruitment of CBP to the GAS element of the IRF-1 promoter and induction of IRF-1 . Taken together, these observations support a role for IRF-1 signaling in mammary gland homeostasis and p53-independent apoptosis.
Although p53 plays a pivotal role in apoptosis, not all apoptotic signaling requires the presence of p53. IRF-1 plays an important role in p53-independent response to DNA damage and is able to promote apoptosis in p53(À) cells (Tamura et al., 1995; Ossina et al., 1997; Porta et al., 2005) . There is evidence that IRF-1 may act in parallel with p53 to promote apoptosis and therefore, loss of IRF-1 would promote the survival of HMECs that had acutely lost p53 function. As here we observe that recruitment of CBP to the IRF-1 GAS element promotes induction of IRF-1, loss of CBP may also promote survival of p53(À) HMECs.
In these studies, we observe that rECM, similar to rapid Tam signaling, promotes apoptosis through induction of IRF-1. Both rECM-and Tam-induced apoptosis are associated with induction of a subset of ISGs, ISG15, IFI 35, (Table 1) . Taken together, our studies show that both rECM and rapid Tam signaling induce apoptosis through signaling pathways that converge on IRF-1 and are consistent with recent reports highlighting the importance of IRF-1-signaling in mammary gland homeostasis and estrogen signaling. In addition, our studies also provide evidence that IRF-1 promotes apoptosis in acutely damaged HMECs independent of p53 expression. IRF-1 and p53 are thought to participate in parallel damage response pathways. Therefore, if mammary epithelial cells are acutely damaged through loss of p53 function, IRF-1-signaling represents an alternative pathway to eliminate p53-damaged cells. Taken together, these results provide evidence that both Tam and rECM transcriptionally activate IRF-1 and support an important role for IRF-1 in mediating p53-independent apoptosis in mammary epithelial cells.
Methods
Small-scale semi-solid rECM culture, cell proliferation and integrin blocking Retroviral transduction was performed as described previously ). HMECs were grown in rECM and proliferation assessed by Ki-67 staining as described previously . Integrin blocking experiments were as published previously .
Large-scale high-density liquid rECM culture Cells were plated at high density (2.5 Â 10 7 /25 cm 2 ) in flasks treated with poly[2-hydroxyethyl methacrylate (poly-HEMA)]. Cells were grown in Standard Media with 1:100 dilution (v:v) of growth factor-depleted rECM (Growth Factor-Depleted Matrigel, Discovery Labware, Bedford, MA, USA).
Differential gene expression studies Expression data for approximately 5600 full-length human genes were collected using Affymetrix GeneChip HuGeneFL arrays and relative transcript levels were tested by semiquantitative RT-PCR as described previously . IFN ELISA IFN ELISA was performed as per manufacturer's instructions using the commercial IFN-a, IFN-b (Biosource International, Camarillo, CA, USA) and IFN-g (Pharmingen, San Diego, CA, USA) ELISA kits.
Apoptosis and caspase-1/-3 activity Apoptosis and caspase-3 were measured by using the ApopNexin FITC Apoptosis Detection Kit and the CaspaTag Caspase-3 in situ Assay kit, respectively (Chemicon International Inc., Temecula, CA, USA). For Annexin-V quantitation, 100 cells were counted for each time point and the percent of positive cells was determined. Caspase-1/-3 activities were assayed according to the manufacturer's instructions using a caspase-1 (EMD Biosciences Inc., San Diego, CA, USA) or caspase-3 (Clontech, Palo Alto, CA, USA) assay kit.
Chromatin immunoprecipitation assay
ChIP assay was performed by published methods . Antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA: anti-IRF-9 (H-143), anti-CBP (A-22), anti-STAT1 (E-23) or anti-IRF-1 (H-205).
Western blotting
Preparation of cellular lysates and immunoblotting were performed as described previously (Seewaldt et al., 1997) . Antibodies are from Santa Cruz Biotechnology unless noted: IRF-1 (C-20), STAT1 (E-23), phospho-STAT1-Ser727 antibody (Cell Signaling Technology, Beverly, MA, USA), IRF-9 (H-143) and STAT2 (A-7).
Suppression/overexpression of IRF-1 Suppression of IRF-1 with siRNA oligos was as described previously . Overexpression: IRF-1 fulllength cDNA was PCR amplified from HMECs (Yokota et al., 2004) . The full-length IRF-1 cDNA was cloned into the IRES2 DsRed2 vector (DsRed-IRF-1) using the EcoRI ends from the pCR2.1 vector.
IRF-1 promoter pull down IRF-1 promoter pull down was performed as described previously using anti-STAT1 (E-23, Santa Cruz) .
